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Abstract: The prolongation of the QT interval is a relatively rare but serious adverse drug reaction.
It can lead to torsade de pointes, which is potentially life-threatening. The study’s objectives
were: determine the use of QT interval-prolonging drugs in an elderly community-dwelling
population at risk of medication misadventure and identify recommendations regarding the risk
of QT interval prolongation made by pharmacists when performing medication reviews. In a
retrospective evaluation, 500 medication review reports from Australian pharmacists were analysed.
In patients taking at least one QT interval-prolonging drug, the individual risk of drug-induced
QT interval prolongation was assessed. Recommendations of pharmacists to avoid the occurrence
of this drug-related problem were examined. There was a high prevalence of use of potentially
QT interval-prolonging drugs (71% patients), with 11% of patients taking at least one drug with a
known risk. Pharmacists provided specific recommendations in only eight out of 35 patients (23%)
with a high-risk score and taking drugs with known risk of QT interval prolongation. Pharmacists’
recommendations, when present, were focused on drugs with known risk of QT interval prolongation,
rather than patients’ additional risk factors. There is a need to improve knowledge and awareness of
this topic among pharmacists performing medication reviews.
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1. Introduction
A rare but serious adverse drug reaction is the prolongation of the QT interval, meaning
that the section between the Q and T waves in the electrocardiogram is extended [1]. This effect
is at least partially caused by a blockade of the outward rapid potassium current, leading to
extended repolarisation. This may trigger an early after-depolarisation, which in combination with
a heterogenous intracardiac repolarisation, is associated with the onset of torsade de pointes (TdP).
TdP is a polymorphic ventricular tachycardia which can be seen in the electrocardiogram as twisting
QRS complexes, which are responsible for the naming. It can result in sudden cardiac death [1].
Pharmaceutical companies are legally obliged to test new drugs for a potential QT interval-
prolonging effect before gaining regulatory approval [2]. Certain drug classes are well known to
include agents that can induce QT interval prolongation; these include antidepressants, non-sedating
antihistamines, antimicrobials, antipsychotics, and cardiac drugs [3]. There is also an association
between the plasma concentrations of these drugs and the risk of QT interval prolongation [4].
Therefore, clinicians must ensure appropriate dose adjustment in patients with chronic kidney or liver
disease to avoid accumulation of QT interval-prolonging drugs [4]. Furthermore, problems can occur
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due to drug-drug interactions [4]. In particular, the combination of QT interval-prolonging drugs that
are metabolised via cytochrome P450 (CYP450) with CYP450-inhibitors can lead to substantial plasma
level increases [4].
In most cases, a combination of different risk factors is responsible for QT interval prolongation [5].
Besides drugs, some patient-specific risk factors include female gender, increasing age, pre-existing
heart disease, and electrolyte imbalances (particularly hypokalaemia) [5].
The risk of drug-induced QT interval prolongation appears to be frequently overlooked in clinical
practice [6]. Pharmacists are in the ideal position to identify and prevent this risk while conducting
medication reviews [7]. In Australia, accredited pharmacists can perform Government-funded
medication management reviews (Home Medicines Reviews; HMRs), in collaboration with general
practitioners (GPs), for individuals living in the community who are at risk of medication
misadventure [8]. First, the GP selects an eligible patient and refers them to an accredited pharmacist [8].
The pharmacist will visit the patient in their residence to perform the review [8]. Then, the pharmacist
writes a report to the GP with recommendations [8]. Finally, the GP meets with the patient to establish
an individualised medication plan and implement changes if necessary [8].
This study explored the role of pharmacists in identifying and reducing the risk of drug-induced
QT interval prolongation when conducting medication reviews. The aim was to determine the
prevalence of use of QT interval-prolonging drugs in an elderly community-dwelling population at
risk of medication misadventure and to identify recommendations made by accredited pharmacists
regarding QT interval prolongation in medication review reports.
2. Experimental Section
The researchers retrospectively analysed 500 de-identified HMR reports. The HMRs were
performed by nine accredited pharmacists between March 2011 and March 2015. The 500 reports were
a random sample of all the reports of a medication review provider during that period. Patients were
eligible for HMRs according to standard criteria, including taking at least five medications, suspected
non-adherence, recent hospitalisation, or requiring education on the use of medicines [9].
The data extraction was performed in duplicate by two researchers (K.L. and V.H.B).
Data regarding the patient’s demographics, the risk factors for QT interval prolongation,
QT interval-prolonging drugs taken, and any recommendations made by the pharmacist regarding
QT interval prolongation were extracted if the patient took at least one QT interval-prolonging drug.
The CredibleMeds® website (status as of 2015) was used to classify medications into three categories
regarding their potential for inducing QT interval prolongation. ‘Known risk’ category includes drugs
that prolong the QT interval and there is strong evidence of increasing the risk of TdP [10]. ‘Possible
risk’ category includes drugs that can cause QT interval prolongation but lack evidence for a risk
of TdP [10]. ‘Conditional risk’ category includes drugs that under certain circumstances (such as
drug interaction, excessive dose, electrolyte disturbances) can be associated with TdP [10]. The fourth
category of the CredibleMeds® website, drugs that should be avoided in individuals with congenital
long QT syndrome [10], was not assessed in this study. Some examples of drugs listed on the website
are given in Table 1.
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Table 1. Examples of drugs with risk of QT interval prolongation and torsade de pointes (TdP) [10].
Category Known Risk Possible Risk Conditional Risk
Definition
“ . . . prolong the QT
interval AND are clearly
associated with a known
risk of TdP, even when
taken as recommended.”
“ . . . can cause QT
prolongation BUT
currently lack evidence
for a risk of TdP when
taken as recommended.”
“ . . . associated with
TdP BUT only under
certain circumstances of
their use OR by creating
conditions that facilitate
or induce TdP.”
Examples
Amiodarone Aripiprazole Amitriptyline
Azithromycin Buprenorphine Furosemide
Chlorpromazine Clozapine Hydrochlorothiazide
Ciprofloxacin Imipramine Indapamide
(Es-)Citalopram Lithium Loperamide
Domperidone Mirtazapine Pantoprazole
Fluconazole Ofloxacin Quetiapine
Sotalol Venlafaxine Sertraline
For the overall risk assessment for QT interval prolongation, the following factors were
evaluated: increased age (>65 years), female gender, smoking status, obesity (body mass index
≥30 kg/m2), cardiomyopathy, hypertension, arrhythmia, prolonged QT interval, thyroid disturbance,
liver failure, neurological disorders, diabetes, electrolyte imbalances (potassium ≤3.5 mmol/L,
calcium <2.15 mmol/L), inflammation (C-reactive protein >5 mg/L), significant renal impairment
(eGFR ≤30 mL/min/1.73 m2), and drugs with risk of QT interval prolongation [11,12]. In patients
taking at least one QT interval-prolonging drug, individual risk was assessed using these factors
within the RISQ-PATH score (Table 2) [12]. This is a validated tool to predict the risk of QT interval
prolongation and ranges from 0 (low risk) to 40.5 (high risk) for patients’ specific risk factors plus the
sum of the score associated with QT interval-prolonging drugs [12]. Patients with a score of 10 or
above are considered as being at high risk of developing drug-induced QT interval prolongation [12].
The ACT Health Human Research Ethics Committee had granted ethics approval for the project
(ETHLR.15.116).
Table 2. Risk factors for QT interval prolongation and their corresponding multiplier (according to
RISQ-PATH score [12]).
Risk Factor Multiplier
Age ≥65 years old 3.0
Female gender 3.0
Smoking status 3.0
BMI ≥30 kg/m2 1.0
Cardiomyopathy 3.0
Hypertension 3.0
Arrhythmia 3.0
Existing prolonged QT interval 6.0
Thyroid disturbances 3.0
Liver failure 1.0
Neurological disorders (stroke, tumour, infection, trauma) 0.5
Diabetes 0.5
Hypokalaemia (≤3.5 mmol/L) 6.0
Hypocalcaemia (<2.15 mmol/L) 3.0
Inflammation (CRP >5 mg/L) 1.0
Renal impairment (eGFR ≤30 mL/min/1.73 m2) 0.5
Known risk QT interval-prolonging drug 3.0 per drug
Possible risk QT interval-prolonging drug 0.5 per drug
Conditional risk QT interval-prolonging drug 0.25 per drug
Abbreviations: BMI = body mass index, CRP = C-reactive protein, eGFR = estimated glomerular filtration rate.
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3. Results
A total of 500 HMR reports were analysed. After duplicate reports (n = 41) were excluded,
459 HMR reports remained. In these 459 patients, 11.3% (52/459) were taking at least one drug with
known risk, 13.5% (62/459) were taking at least one drug with a possible risk, and 63.4% (291/459)
were taking at least one drug with a conditional risk. Overall, 325 patients (70.8%) were taking at least
one drug associated with the risk of QT interval prolongation (Table 3). Their mean age was 76 (± 12)
years. The most commonly prescribed QT interval-prolonging drug overall was hydrochlorothiazide,
which is associated with conditional risk (90 of 459 reviewed patients; 19.6%), while citalopram and
escitalopram were the most frequently taken known risk drugs, each with a prevalence of 2.8% (13/459)
(Table 3). Eleven patients took a maximum of four QT interval-prolonging drugs (Figure 1). In total,
557 drugs were being taken that carried some risk of QT interval prolongation, including drugs with
known risk (9.9%), possible risk (12.4%), and conditional risk (77.7%).
Table 3. Baseline characteristics of patients taking QT interval-prolonging drugs (n = 325) and
commonly taken QT interval-prolonging medication (n = 459).
Baseline Characteristics of Patients Mean± SD (Range) or n (%)
Age (years) 76 ± 12 (20–97)
Medications/supplements per patient 10 ± 3 (2–20)
Chronic medical conditions per patient a 6 ± 3 (1–15)
Female 211 (64.9)
QT Interval-Prolonging Drug Patients n (%) Risk
Hydrochlorothiazide 90 (19.6) Conditional
Pantoprazole 89 (19.4) Conditional
Furosemide 85 (18.5) Conditional
Indapamide 36 (7.8) Conditional
Sertraline 31 (6.8) Conditional
Amitriptyline 23 (5.0) Conditional
Mirtazapine 21 (4.6) Possible
Metoclopramide 18 (3.9) Conditional
Venlafaxine 15 (3.3) Possible
Citalopram 13 (2.8) Known
Escitalopram 13 (2.8) Known
a data available for n = 312; Abbreviation: SD = standard deviation.
The risk of drug-induced QT interval prolongation, using the RISQ-PATH score, was calculated
for those 325 patients taking QT interval-prolonging drugs. The mean score was 9.4 (± 3.4); 49.5% of
the patients had a score between 6 and 10 (161/325), and 42.2% of patients (137/325) had a score of
10 or higher, which was defined as high risk. Of all patients taking QT interval-prolonging drugs,
98.9% (321/325) had at least one patient-specific risk factor for QT interval prolongation, with older
age being the most common of these (n = 275). The prevalence of various patient-specific risk factors is
displayed in Figure 1.
Out of 35 patients with a high-risk RISQ-PATH score of≥10 and taking drugs having a known risk
of QT interval prolongation, pharmacists provided specific recommendations regarding QT interval
prolongation in only eight cases (23%). In a further eight cases (23%) they provided unspecific advice
(e.g., risk of interaction, not suitable for patient, or recommended dose reduction), in six cases (17%)
they mentioned a different potential adverse effect of the drug, and in the remaining 13 cases (37%) the
pharmacists did not make any recommendation. It should be noted that donepezil was added to the
CredibleMeds® website in March 2015. That means that these results included one medication review
report with unspecific advice regarding donepezil and two reports without any recommendations
regarding donepezil, that were written before the drug was listed as “known risk”.
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Overall, in 15 of 325 HMR reports (4.6%) for patients taking potential QT interval-prolonging 
drugs, the pharmacists specifically mentioned patients being at risk of QT interval prolongation. The 
comments were regarding excessive doses of specific drugs (citalopram n = 2, escitalopram n = 2, 
domperidone n = 2), prescription of specific drugs (tricyclic antidepressants n = 5, sotalol n = 1), and 
pharmacotherapy with several QT interval-prolonging drugs concomitantly (n = 9); some 
recommendations comprised several of these aspects. The suggested interventions were monitoring 
patients closely (n = 5), monitoring electrolytes (n = 2), change of drug (n = 4), withdrawal (n = 4), dose 
reduction (n = 4), and specialist referral (n = 3); for some patients several interventions were 
suggested. The median risk score for QT interval prolongation in these 15 patients was 11.25 (ranging 
from 1.75 to 16.25). 
4. Discussion 
Overall, 71% of medication review recipients were taking at least one drug associated with the 
risk of QT interval prolongation, including 11% taking at least one drug with known risk; yet, 
pharmacists’ recommendations relating to this risk were uncommon. Examples of implicated drugs 
included citalopram, escitalopram, domperidone, and tricyclic antidepressants. The former three 
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verall, in 15 of 325 HMR reports (4.6%) for patients taking potential QT interval-prolonging
drugs, the pharmacists specifically mentioned patients being at risk of QT interval prolongation.
The comments were regarding excessive doses of specific drugs (citalopram n = 2, escitalopram
n = 2, domperidone n = 2), prescription of specific drugs (tricyclic antidepressants n = 5, sotalol
n = 1), and pharmacotherapy with several QT interval-prolonging drugs conco itantly (n = 9);
some recommendations comprised several of these aspects. The suggested interventions were
monitoring patients closely (n = 5), monitoring electrolytes (n = 2), change of drug (n = 4), withdrawal
(n = 4), dose reduction (n = 4), and specialist referral (n = 3); for some patients several interventions
were suggested. The median risk score for QT interval prolongation in these 15 patients was 11.25
(ranging from 1.75 to 16.25).
4. Discussion
Overall, 71% of medica review recipients were taking at l ast one drug ass ciated with
the isk of QT interval prolong tion, including 11% taking at lea t one drug with k own risk; yet,
phar acists’ recommendations r lating o this risk were uncommon. Examples of implicated drugs
included citalopram, escitalopram, domperidone, and tricyclic antidepressants. T e former three hav
a high risk of QT interval rolongation; for the latter, the risk is mainly conditional [10]. In addition,
the pharmacists’ recommendations, when present, to identify a d pr vent QT interval prolongat on
were mainly focused on drugs rather than patients’ other risk factors.
Previous studies have shown low awareness of the risk of TdP among healthcare
professionals [13,14], which also seemed to be the case here. A recent study successfully tested
the effectiveness of an e-learning program for community pharmacists about the risks of QT interval
prolongation, that can assist pharmacists in identifying and preventing this uncommon but dangerous
adverse drug effect [15]. Studies have also successfully shown that, with appropriate decision aids,
pharmacists are capable of supporting physicians in the prevention and monitoring of QT interval
prolongation [16,17].
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This study had a few limitations. Since the study was retrospective, the research team was not
able to check the validity of the recorded data. In some HMR reports, data for the risk calculation was
not available, especially regarding the pathology data. That might have led to an underestimation of
the prevalence of risk factors (e.g., electrolyte imbalances or co-morbidities) since patients without the
recorded data were categorized as not having the risk factor. The CredibleMeds® drug list is updated
when new evidence regarding a drug’s potential to induce QT interval prolongation is identified.
The reports included in this study were written over a period of four years. This means that at the
point of the medication review, a drug might not have been listed. This limitation was minimised by
using a list with status as of 2015.
The findings of this research could stimulate the development of an action plan for pharmacists
to support prescribers to better prevent the occurrence of drug-associated TdP and potentially sudden
cardiac death. An education module about QT interval prolongation could be implemented in
pharmacy undergraduate and continuing professional education programs. Other authors have also
called for more intense training in cardiac safety at pharmacy schools [18].
5. Conclusions
There is an appreciable risk of drug-induced QT interval prolongation among patients undergoing
medication reviews. Furthermore, the presence of other risk factors, such as older age and gender,
puts many patients at additional risk of this adverse event. Pharmacists’ recommendations in
medication reviews, when present, were targeted on drugs with known risk of QT interval prolongation,
rather than patients’ additional risk factors. There is a need to improve knowledge and awareness of
this topic amongst pharmacists performing medication reviews.
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